Drug Approval | June 17, 2024
Imfinzi approved in the US for endometrial cancer
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
This is the first peptide product approval from the USFDA received by Alembic Pharmaceuticals
India's healthcare sector anticipates telemedicine reaching US$ 5.4 billion by 2025, with AI growing at 45% by 2024 and Healthtech jobs increasing 15-20%
Abdel has held leadership positions at Bayer, Merck, Catalent, Lonza, and KBI Biopharma,
Department presents a detailed overview of the Pharma and MediTechsector and gives a detailed presentation on the activities of Department
First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting
As on 31st March 2024, Jubilant Pharmova Limited reported Gross Debt at Rs. 3,414 crore
Co-founder and previous CEO Lowry Curley becomes Chief Scientific Officer
Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older
Azilsartan Medoxomil and Chlorthalidone Tablets had annual sales of US$ 77.9 mn in the United States (IQVIA MAT March 24).
Subscribe To Our Newsletter & Stay Updated
